Insulet (NASDAQ:PODD) Trading Down 5.2% – Should You Sell?

Insulet Corporation (NASDAQ:PODD)’s stock price was down 5.2% during trading on Monday . The stock traded as low as $158.01 and last traded at $155.8650. 61,738 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,243,904 shares. The stock had previously closed at $164.48.

Analysts Set New Price Targets

A number of research analysts have recently commented on PODD shares. Wells Fargo & Company reduced their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. BTIG Research dropped their price objective on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, May 26th. The Goldman Sachs Group restated a “buy” rating and set a $205.00 target price on shares of Insulet in a research report on Wednesday, May 27th. Oppenheimer decreased their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Sanford C. Bernstein lowered their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $237.83.

Insulet Price Performance

The stock has a market capitalization of $11.02 billion, a PE ratio of 36.82, a P/E/G ratio of 1.15 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm’s 50 day simple moving average is $155.23 and its 200 day simple moving average is $215.38.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the company earned $1.02 EPS. The firm’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.36% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Larson Financial Group LLC boosted its holdings in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet in the 4th quarter worth approximately $26,000. DV Equities LLC purchased a new position in Insulet in the 4th quarter worth approximately $28,000. Elyxium Wealth LLC bought a new stake in Insulet in the fourth quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. bought a new stake in Insulet in the fourth quarter valued at approximately $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.